136 related articles for article (PubMed ID: 32903504)
1. Neglected, Drug-Induced Platinum Accumulation Causes Immune Toxicity.
Zhang Y; Zheng J; Jiang Y; Huang X; Fang L
Front Pharmacol; 2020; 11():1166. PubMed ID: 32903504
[TBL] [Abstract][Full Text] [Related]
2. Platinum Accumulation and Cancer-Related Fatigue, Correlation With IL-8, TNF-α and Hemocytes.
Zhang Y; Huang X; Feng S; Chen C; Guo D; Fang L
Front Pharmacol; 2021; 12():658792. PubMed ID: 34557089
[TBL] [Abstract][Full Text] [Related]
3. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
5. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.
Tsimberidou AM; Said R; Culotta K; Wistuba I; Jelinek J; Fu S; Falchook G; Naing A; Piha-Paul S; Zinner R; Siddik ZH; He G; Hess K; Stewart DJ; Kurzrock R; Issa JP
Clin Epigenetics; 2015; 7(1):29. PubMed ID: 25806091
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
9. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 442():1-306. PubMed ID: 12595921
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
13. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
14. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
15. Organic cation transporters are determinants of oxaliplatin cytotoxicity.
Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM
Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202
[TBL] [Abstract][Full Text] [Related]
16. [Effects of medicated serum prepared with Chinese herbal medicine Changweiqing on pharmacokinetics of oxaliplatin in colon cancer cells].
Zhang Y; Sun XW; Xu JH; Lu H; Fan ZZ; Sun J; Zhang XX
Zhong Xi Yi Jie He Xue Bao; 2012 Aug; 10(8):901-10. PubMed ID: 22883407
[TBL] [Abstract][Full Text] [Related]
17. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
19. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]